Pall Partners with BioFactory Competence Center to Launch Practical Continuous Bioprocessing Courses
News Nov 13, 2017
Pall Corporation is pleased to partner with the BioFactory Competence Center (BCC) in Fribourg, Switzerland to launch new training courses in early 2018 focused on continuous bioprocessing advances. The courses will detail the state of the industry and the advantages and practical implications of transitioning from batch to semi- or fully-continuous bioprocess methodologies. Pall Life Sciences’ Cadence platform technologies will be featured for hands-on training. Registration for standard sessions will be available through the BCC beginning in December and custom sessions are available upon request.
“The BCC launched in January 2016 to deliver theoretical and practical biopharmaceutical industry training on everything from basic aseptic techniques to more detailed applications focused training from upstream to downstream processing, covering cell culture, cell separation, chromatography and concentration, comparing single-use vs. traditional approaches,” stated Ian Marison, CEO and co-founder of the BCC. “As industry interest grows in the advantages of continuous bioprocessing, we felt it necessary to introduce specialized training for successfully navigating this next-generation of drug making.”
The upcoming courses will highlight key advantages of integrated continuous bioprocessing, and how best to leverage semi- or fully- continuous manufacturing technologies based on current resources and future goals. The practical sessions will feature Pall Life Sciences’ process development scale technologies, including the Cadence Acoustic Separator for continuous clarification and separation, the Cadence BioSMB PD system for multi-column chromatography, and the Cadence Inline Concentrator for continuous concentration at various process steps.
“As drug manufacturers look to shift from batch to continuous processing for both small and large molecule drugs, information-sharing and continued education have become key drivers of advancement,” said Peter Levison, Senior Marketing Director of Downstream Processing at Pall Corporation. “These unique training courses have been designed around real-life situations, with hands-on access to enabling technologies, and we are proud to support them.”
In addition to the new courses, plans exist to build a dedicated continuous bioprocessing facility in Fribourg for education on, and application of continuous bioprocessing technologies. The facility will also feature Pall Cadence platform technologies.
Small Tweak Makes Progress Towards Improved Flu TreatmentNews
Researchers report that a tweak to a small-molecule drug shows promise for future production of new antiviral therapies that could help patients, regardless of the strain with which they are infected.READ MORE
Switch Discovered to Convert Blood Vessels to Blood Stem Cells During Embryonic DevelopmentNews
Findings could aid research into creating new blood cells for transplants and understanding cancer metastasis.READ MORE
Malaria Prevention: New Antibody Targets Unique Binding SiteNews
Scientists have discovered a human antibody that, when tested in mice, prevented malaria infection by binding a specific portion of a surface protein found in almost all strains of the malaria parasite worldwide.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018